Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial

European Neuropsychopharmacology

Volumn 26, Issue 12, 2016, Pages 1950-1959

  Beraha, Esther M ^a   Salemink, Elske ^a   Goudriaan, Anna E ^a,b   Bakker, Abraham ^f   de Jong, David ^a   Smits, Natasha ^c   Zwart, Jan Willem ^c   Geest, Dick van ^d   Bodewits, Pieter ^e   Schiphof, Tom ^d   Defourny, Harma ^c   van Tricht, Mirjam ^a   van den Brink, Wim ^a   Wiers, Reinout W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Arkin Institute for Mental Health Care   (Netherlands)

^c SolutionS Center   (Netherlands)

^d U Center   (Netherlands)

^e The Home Clinic   (Netherlands)

^f RoderSana Addiction Treatment   (Netherlands)

Author keywords

Alcohol dependence; High dose baclofen; Randomised placebo controlled trial

Indexed keywords

BACLOFEN; PLACEBO; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER IDENTIFICATION TEST; ALCOHOLISM; ARTICLE; BECK DEPRESSION INVENTORY; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DSM-IV; EUROPEAN ADDICTION SEVERITY INDEX; FATIGUE; FEMALE; FRANCE; GENERIC ASSESSMENT OF SIDE EFFECTS; HEALTH PROGRAM; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE ASSESSMENT; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONTREAL COGNITIVE ASSESSMENT; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DRINKING SCALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PENN ALCOHOL CRAVING SCALE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SPIELBERGER STATE TRAIT INVENTORY; TIMELINE FOLLOW BACK; TREATMENT DURATION; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; RECURRENT DISEASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; BACLOFEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GABA AGONISTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84999274235     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.10.006     Document Type: Article

References (34)

1. Addolorato, G., Caputo, F., Capristo, E., Domenicali, M., Bernardi, M., Janiri, L., Agabio, R., Colombo, G., Gessa, G.L., Gasbarrini, G., Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol Alcohol. 37 (2002), 504–508.
2. Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Bedogni, G., Caputo, F., Gasbarrini, G., Landolfi, R., Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomised, double-blind, placebo-controlled trial. Alcohol Alcohol. 46 (2011), 312–317.
3. Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D׳Angelo, C., Caputo, F., Zambon, A., Haber, P.S., Gasbarrini, G., Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370 (2007), 1915–1922.
4. Ameisen, O., The End of My Addiction, 2008, Macmillan, New York.
5. Ameisen, O., Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 40 (2005), 147–150.
6. Anton, R.F., Moak, D.H., Latham, P., The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol. Clin. Exp. Res. 19 (1995), 92–99.
7. Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mason, B.J., Mattson, M.E., Miller, W.R., Pettinati, H.M., Randall, C.L., Swift, R., Weiss, R.D., Williams, L.D., Zweben, A., Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomised controlled trial. J. Am. Med. Assoc. 295 (2006), 2003–2017.
8. Beck, A., Ward, C., Mendelson, M., Beck depression inventory (BDI). Arch. Gen. Psychiatry 4 (1961), 561–571.
9. Blanken, P., Hendriks, V., Pozzi, G., Tempesta, E., Hartgers, C., Koeter, M., European Addiction Severity Index, EuropASI. A Guide to Training and Administering EuropASI Interviews. 1994, EMCDDA, Lisbon.
10. Bucknam, W., Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 42 (2007), 158–160.
11. Carter, L.P., Koek, W., France, C.P., Behavioral analyses of GHB: receptor mechanisms. Pharmacol. Ther. 121 (2009), 100–114.
12. Chaignot, C., Weill, A., Ricordeau, P., Alla, F., Use in France of Baclofen for Alcohol Dependence from 2007 to 2013: cohort Study Based on the Databases SNIIRAM and PMSI. Thérapie 70 (2015), 443–453.
13. Colombo, G., Vacca, G., Serra, S., Brunetti, G., Carai, M. a M., Gessa, G.L., Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology 167 (2003), 221–224.
14. Davidoff, R.A., Antispasticity drugs: mechanisms of action. Ann. Neurol. 17 (1985), 107–116.
15. de Beaurepaire, R., The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series. Front. Psychiatry, 5, 2014, 143.
16. European Medicines Agency, Annual Report of the European Medicines Agency 2010, 2011, European Medicines Agency, London.
17. Feys, F., Bekkering, G.E., Singh, K., Devroey, D., Do randomised clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?. Syst. Rev. 3 (2014), 1–14.
18. Flannery, B.A., Volpicelli, J.R., Pettinati, H.M., Psychometric properties of the Penn alcohol craving scale. Alcohol. Clin. Exp. Res. 23 (1999), 1289–1295.
19. Garbutt, J.C., Kampov-Polevoy, A.B., Gallop, R., Kalka-Juhl, L., Flannery, B.A., Efficacy and safety of baclofen for alcohol dependence: a randomised, double-blind, placebo-controlled trial. Alcohol. Clin. Exp. Res 34 (2010), 1849–1857.
20. Koob, G., Volkow, N., Neurocircuitry of addiction. Neuropsychopharmacology 35 (2010), 217–238.
21. Lehert, P., Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol., 1992, 157–163.
22. Marsot, A., Imbert, B., High variability in the exposure of baclofen in alcohol‐dependent patients. Alcohol. Clin. Exp. Res. 38 (2014), 316–321.
23. Müller, C.A., Geisel, O., Pelz, P., Higl, V., Krüger, J., Stickel, A., Beck, A., Wernecke, K.-D., Hellweg, R., Heinz, A., High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomised, placebo-controlled trial. Eur. Neuropsychopharmacol. 25 (2015), 1167–1177.
24. Nasreddine, Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.L., Chertkow, H., The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53 (2005), 695–699.
25. Ponizovsky, A., Rosca, P., Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomised, double-blind, placebo-controlled trial with 1year follow-up. J. Subst. Abus. Treat. 52 (2015), 24–30.
26. Rehm, J., Shield, K.D., Gmel, G., Rehm, M.X., Frick, U., Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur. Neuropsychopharmacol. 23 (2013), 89–97.
27. Rief, W., Glombiewski, J.A., Barsky, A.J., 2009. Generic assessment of side effects: GASE. www.GASE-scale.com.
28. Saunders, J., Aasland, O., Barbor, T., De La Fuente, J., Grant, M., Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88 (1993), 791–804.
29. Sheehan, D., Lecrubier, Y., Sheehan, K., Amorim, P., Janavs, J., Weiller, E., Dunbar, G., The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998), 22–23.
30. Sobell, L.C., Sobell, M.B., 1992. Timeline follow-back, In: Measuring alcohol consumption. Humana Press, 41-72.
31. Spielberger, C.D., State‐Trait Anxiety Inventory, 2010, Wiley & Sons, New York.
32. van den Brink, W., Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Curr. Drug Abus. Rev. 5 (2012), 3–31.
33. van den Brink, W., Aubin, H., Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomised controlled 6-month studies. Alcohol Alcohol. 48 (2013), 570–578.
34. World Health Organization, 2014. Global status report on alcohol and health.